Navigation Links
BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
Date:3/16/2009

EXTON, Pa., March 16 /PRNewswire/ -- BioTrends Research Group, Inc. has been covering the biologics market for Psoriasis and RA through its TreatmentTrends(TM) series which are syndicated primary research reports based on self reported survey data collected from Dermatologists and Rheumatologists. The company is now expanding these offerings in the form of ChartTrends(TM) reports which aim to compare self-reported treatment patterns with actual patient level data.

The ChartTrends(TM) reports will each offer comprehensive insight into the management and use of biologics used in the treatment of Rheumatoid Arthritis (RA) and Psoriasis. Each report is derived from analysis of actual patient chart data and laboratory results collected from over 1,000 RA and Psoriasis patients currently being treated with biologics. The retrospective audit captures a wide range of patient demographic data, the range of dose variability, co-morbidities, concomitant medications, and laboratory values for the past year. Medication changes and actions taken during office visits are highlighted to understand the triggers for therapy initiation and adjustment. The final report also compares the self-reported practice patterns with actual patient records in order identify gaps in care.

These studies are being undertaken to understand the treatment algorithm for biologic initiation, how each of the biologic brands is typically used, what triggers brand switching, and what patient characteristics (age, co-morbidities, insurance type) influence treatment decisions. Additionally, the study will assess familiarity and interest in several late stage biologics in development (Roche's ACTEMRA, Centocor's SIMPONI, and UCB's CIMZIA in RA and Centocor's STELARA and Abbott's ABT-874 in Psoriasis). BioTrends, which has been offering ChartTrends(TM) reports since 2005, plans to publish the findings in June.<
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
2. As SEIU Prepares Hostile Takeover of United Healthcare Workers, Surveillance of Local Union Office Ends in Assault by Off-Duty Police Officer
3. SCAIs Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field
4. Irvine Pharmaceutical Services Enhances Staff, Prepares for Innovative Expansion
5. CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
6. Gilbert Hospital Prepares for Flu Season
7. American Red Cross Prepares for Tropical Storm Fay in Florida
8. New Anti-Cellulite Treatment Prepares Women for Falls Short Skirts
9. New Anti-Cellulite Treatment Prepares Women for Warmer Weather and Beyond
10. First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
11. OrthoSynetics(TM) Expands Sales Team; Prepares to Grow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 BamboofloorChina.com is ... its products have won great appreciation from the global ... is working hard to make more excellent items. All ... ready to help all clients. , The company ... panels to its website. Furthermore, the company’s marketing ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... personality style and prolonged stress may have a heightened ... Tracking 800 women over nearly four decades, Swedish scientists ... moody -- which they defined as neurotic -- and ... Alzheimer,s compared to women scoring lowest in these traits. ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... a major highway may raise your risk for high blood ... postmenopausal women, those who lived within 109 yards of a ... high blood pressure than women living at least half a ... study highlight the importance of our physical environment on our ...
(Date:10/2/2014)... By Amy Norton HealthDay ... adults who have trouble smelling the roses -- literally -- may ... new research suggests. In a study of over 3,000 older ... as rose, orange and peppermint were more than three times as ... a sharp sense of smell. In fact, anosmia -- the ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3
... Sept. 2 A survey of emergency medical services (EMS) ... of workplace safety cultureproviding a tool that might point to ... of Pittsburgh School of Medicine. The study ... Prehospital Emergency Care and now available online, analyzed survey ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Sept. ... mentally stimulating activities have pros and cons when it comes ... prior research, the study finds that such mental activity may ... But folks who loved these pursuits actually displayed a ...
... Sept. 1 (HealthDay News) -- A new study is linking ... non-fatal heart attacks and stroke, although taking the drug did not ... history of heart problems. The finding is stirring mixed reactions ... was funded by Meridia,s maker, Abbott, the findings are generally in ...
... September issue of the Journal of the American Geriatrics ... have a greater risk for dementia than Veterans without PTSD, ... Exposure to life threatening events, like war, can cause PTSD, ... symptoms such as avoiding things or people that remind a ...
... Engineering at Harvard and from Boston University have discovered ... microscopic forms of lifebacteria. Their findings appear in ... studying the development of antibiotic-resistant strains of bacteria, the ... doses of antibiotics are those in which a few ...
... Lee Phillips HealthDay Reporter , WEDNESDAY, Sept. ... inflammation in those with lupus, but the anti-clotting drug ... disease, a new study suggests. Platelets, which are ... clotting, are suspected to be involved in lupus, explained ...
Cached Medicine News:Health News:Safety cultures in EMS agencies vary widely, Pitt study finds 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 3Health News:Diet Pill Meridia Ups Heart Attack Risk: Study 2Health News:Diet Pill Meridia Ups Heart Attack Risk: Study 3Health News:Pivotal study finds link between PTSD and dementia 2Health News:New research finds evidence of charitable behavior in bacteria 2Health News:Overactive Blood Platelets May Play Role in Lupus 2
(Date:10/2/2014)... Oct. 2, 2014   West Pharmaceutical Services, Inc. ... in innovative solutions for injectable drug administration, announced today ... include a new site in Waterford, Ireland ... for insulin injector cartridges and other high-value packaging components, ... biotech customers. Once operational, this new site could bring ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014  Abaxis, Inc. ... manufacturing point-of-care instruments and consumables for the medical, research, ... to the veterinary and research markets in ... entered into a definitive distribution agreement with Patterson Veterinary ... and promote the full line of Abaxis veterinary products ...
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... 9, 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and ... 767905/014 and,provided an update on the clinical ... Phase 3, double blind, placebo-controlled (12,month) study, ... and,tolerability of alvimopan 0.5 mg twice daily ...
... Educate on Good,Diabetes Management and How to Reduce ... 10, 2007 /PRNewswire/ -- A first-of-its-kind,report looking at ... shows that an estimated three out of five ... least one of the other,serious health problems commonly ...
Cached Medicine Technology:GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... The AFX (Air Fluid eXchange) ... lens designed for use in ... to its use as a ... the low profile and sutureless ...
... The 45° Prism ... fundus pathologies and are ... detachments (PDR, BRVO etc.) ... They can be used ...
Medicine Products: